1 Followers
25 Following
chaitanyag11

chaitanyag11

Arginine Market by Pharmaceuticals & Healthcare Analysis 2018 to 2026

Arginine, which is also known as L-arginine, is an essential amino acid for humans. Arginine is present in all protein-containing foods such as grains, beans, nuts, meat, dairy products, and eggs, and it is also synthesized in the body from glutamine via citrulline amino acid. Arginine plays an important role in cell division, wound healing, removal of ammonia from the body, boosting immune function, and in the release of hormones.

Arginine Market: Drivers

For instance, an article published in PLOS One journal in May 2015 suggested that arginine might alter multi-species oral biofilm development and may also break down dental plaque, which could help millions of people in preventing dental decay and gum diseases.

Furthermore, new product development is expected to fuel growth of the arginine market. For instance, in October 2018, Nutrition 21, LLC announced that its clinically substantiated ingredient, Nitrosigine, is now included in Elite Gold NX6 product. Elite Gold NX6 is a polymer of arginine silicate, which is stabilized by inositol. Therefore, the development of Elite Gold NX6 with nitrosigine ingredient will help in boosting nitric oxide levels, which is found to be a key factor in generating greater blood flow and vasodilation in working muscles.

Download the PDF brochure:

https://www.coherentmarketinsights.com/insight/request-pdf/2238

Arginine Market: Restraint

Product recalls for arginine drug packaging is expected to hamper growth of the arginine market. For instance, in November 2017, Therapeutics Goods Administration (TGA) of Australia recalled Apotex Inc.’s Apo-Perindopril Arginine 2.5 mg, 5 mg, and 10 mg tablet batches from the market due to contamination of tablet bottles with dark particles of silica. This contamination was classified as a quality defect. Apo-Perindopril Arginine is indicated for high blood pressure, heart failure or coronary artery disease. Moreover, United Pharmacy recalled two lots of a compounded injectable glutamine/arginine/carnitine product, GAC-12 and GAC-13, in November 2017.

Arginine Market: Regional Analysis

On the basis of region, the global arginine market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

North America is projected to account for the largest share in the arginine market due to new product launches in the U.S. For instance, Pfanstiehl, Inc., a U.S.-based company, in September 2018, launched a new high-purity, low-endotoxin, and low-metal, L-Arginine, which meets the U.S. Pharmacopoeia (USP), European Pharmacopoeia (EP), Japan Pharmacopoeia (JP), and Chinese Pharmacopoeia (ChP) standards. This is the first amino acid that Pfanstiehl, Inc. launched and manufactured in the U.S. under strict current good manufacturing practice (cGMP) and International Conference on Harmonization (ICH) Q7 compliant conditions.

Asia Pacific region is also expected to witness significant growth in the arginine market, owing to expansions of key players for the production of arginine formulations. For instance, in April 2018, CJ CheilJedang, a China-based firm, announced to expand its L-Arginine and L-Citrulline production at its Jombang plant in Indonesia, which will be effective from 2019. By this expansion, the company also plans to manufacture its product, L-Citrulline (precursor of Arginine in body), simultaneously in both China and Indonesia.

Click To Reading More On Arginine Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

Visit our news Website: https://www.coherentwire.com

Jaundice Meter Market Driver,Growth,Size And Insights

The bilirubin levels are raised in body due to condition of hyperbilirubinemia, which further results in jaundice. Jaundice meter also called as bilirubinometer is commonly used in neonatal jaundice measurement. It is non-invasive, cost effective, and real-time bilirubin screening device.

Jaundice Meter Market Driver

Advancements in technology for jaundice meters is expected to drive growth of jaundice meter market. For instance, according to American Academy of Pediatrics, August 2017, BiliCam is a smartphone-based non-invasive medical device, which uses on-device camera to monitor yellow discoloration of skin due to excess deposition of bilirubin. Newborn images are collected in a standardized way on the phone. The color (intensity of yellow discoloration) data in the image are used to estimate the bilirubin level. 

Jaundice Meter Market Restraint

Serious injuries caused due to misuse of jaundice meter is expected to hamper growth of the jaundice meter market. For instance, in June 2018, Food and Drug Administration (FDA) recalled, Draeger Medical Systems’, Jaundice Meter JM-103 and JM-105 models, as many users misinterpreted display messages for out of range values for bilirubin using such system,  which can result in serious injuries such as brain damage.

Download the PDF brochure:

https://www.coherentmarketinsights.com/insight/request-pdf/2246

Jaundice Meter Market – Regional Analysis

On the basis of region, the global jaundice meter market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

North America is expected to witness significant growth in the jaundice meter market attributed to high number of jaundice cases. For instance, according to University of California San Francisco report 2018, Jaundice is a common condition in newborns, affecting 50 percent to 60 percent of full-term babies and 80 percent of premature born in the U.S.

Europe is projected to witness remarkable growth in the jaundice meter market due to increase in development of jaundice meters by key players and collaborations among them.  For instance, in 2016, DELTA Medical International, a U.K. based company, received distribution rights for non-invasive jaundice meters of M & B Electronic in U.K. and Ireland. This non-invasive jaundice meter provide instant results for bilirubin levels from blood, with easy handling. Moreover, DELTA Medical International has undergone clinical study in 2017 for Delta Medical International transcutaneous jaundice meter, which reported statistical correlation between the transcutaneous measurements and serum bilirubin tests.

Asia Pacific is estimated to grow at significant rate in the jaundice meter market due to increasing awareness regarding pediatrics and neonatal care. For instance, on 28th world congress on Neonatology and Perinatology is to be held in Japan in May 2019. Conference will be highlighting on latest and exciting innovations, trends, and inventions in fetal and neonatal care. The conference is expected to be an international platform for presenting research regarding diagnosis, prevention and management of neonatal diseases, which in turn can contribute to the improving neonatology and child health.

Click To Reading More On Jaundice Meter Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

Visit our news Website: https://www.coherentwire.com

Calciphylaxis Treatment Market Sales Volume, Sales Price, Sales Revenue Analysis

The global calciphylaxis treatment market size was valued at US$ 1,097.7 million in 2017 and is expected to witness a CAGR of 9.6% over the forecast period (2018 – 2026). 
Calciphylaxis or Calcific Uremic Arteriolopathy (CUA) is the most severe form of cardiovascular calcification in dialysis patients. It starts with a calcification of small peripheral vessels and quickly spreads in the body. Moreover, people suffering from calciphylaxis have an imbalance in calcium metabolism, which causes calcium to be deposited in arterioles, which eventually leads to the formation of blood clots in the arterioles. Blood clots can cause fat tissues and skin to be deprived of oxygen and nourishment.

According to a data published by National Center for Biotechnology Information (NCBI) 2014 report, calciphylaxis affects around 4% of patients in the late stage of chronic kidney disease and 55% of patients with calciphylaxis die within a year of diagnosis and suffer from painful skin ulcers and a high risk of infection. No effective treatment for calciphylaxis is currently available and its causes are unknown. However, patients suffering from this disease are usually treated with intensive care, including wound management. The occurrence of calciphylaxis is associated with hyperthyroidism.

According to the Journal of General Internal Medicine 2014 study, calciphylaxis has an increasing incidence trend and a 50% mortality rate within the first year of onset. High prevalence of kidney disease is a major factor for incidences of calciphylaxis. According to the National Institute of Diabetes and Digestive and Kidney Diseases Health Information Center, in 2016, over 661,000 Americans had kidney failure and 468,000 of these patients were on dialysis.

Download the PDF brochure:

https://www.coherentmarketinsights.com/insight/request-pdf/2251

Various academic research institutes and companies are focused on developing suitable treatment for calciphylaxis. For instance in March 2018, Sanifit successfully completed a Phase II trial of the first effective treatment for calciphylaxis. Moreover, in 2014, researchers at the National Kidney Foundation reported successful application of intravenous (IV) pamidronate to treat calciphylaxis in patients with End-Stage Renal Disease (ESRD).

Calciphylaxis Treatment Market Restraints

Lack of an appropriate treatment for calciphylaxis is a major factor hindering growth of the global calciphylaxis treatment market. However, increasing research to develop a suitable treatment for the condition is expected to drive growth of the market.

Calciphylaxis Treatment Market - Regional Insights

On the basis of region, the global calciphylaxis treatment market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America calciphylaxis treatment market is expected to foresee major revenue share, owing to increasing government support and funding to treat calciphylaxis patients. According to the National Kidney Disease Education Program study 2015, in the U.S., treatment of chronic kidney disease surpasses US$ 48 billion, annually and the ESRD program consumes 6.7% of the total Medicare budget to care for less than 1% of the covered population.

Asia Pacific calciphylaxis treatment market is expected to witness growth at a significant CAGR, owing to increasing expenditure in treatment of kidney diseases coupled with high prevalence of kidney diseases with diabetes and growing geriatric population base. For instance, according to the National Kidney Disease Education Program study 2015, in Australia, treatment for all current and new cases of kidney failure by 2020 is expected to cost around US$ 12 billion. Moreover, annual cost of dialysis per patient, annually varies between US $35,000 and 55,000 depending on the type of treatment.

Click To Reading More On Calciphylaxis Treatment Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

Memantine Market to Reflect Steady Growth During 2018 – 2026

The drug received European marketing approval in 2002 and the U.S. Food and Drug Administration (U.S FDA) approval in 2003. The generic versions of the drugs are available since 2015. Memantine aids in treatment of moderate to severe dementia associated with Alzheimer's disease. However the drug may show a severe skin reaction called Stevens-Johnson syndrome (associated with painful blisters on the skin) after prolonged use.

Memantine Market– Drivers

Increasing number of pipeline studies for use of memantine are expected to boost growth of the memantine market. For instance, in September 2016, Lille University Hospital started phase I clinical study for assessing the effects of memantine on cognitive behavior of patients associated with Alzheimer’s disease. The study is estimated to be completed by February 2019.

Furthermore, Suven Life Sciences Limited is undergoing phase II clinical study for the comparative study on safety and efficacy of SUVN-502 along with memantine HCl and donezepil HCl for treating moderate Alzheimer’s disease. The study was started in September 2015 and is expected to be completed in May 2019.

Memantine Market– Taxonomy

By Formulation

Tablet,Capsule

By Distribution Channel

Hospital Pharmacies,Retail Pharmacies,Online Pharmacies

Download the PDF brochure:

https://www.coherentmarketinsights.com/insight/request-pdf/2255

Memantine Market– Restraint

Increasing number of expired patents of drugs is a major factor hindering growth of the global memantine market. For instance, according Merz Pharmaceuticals, a Germany-based company, in October 2018, overall licensing income during patented period for memantine decreased due to expiration of patent protection in a majority of markets. For instance, according to Merz Pharmaceuticals, the U.S. licensing income for memantine declined to US$ 138.07 million in 2017-18 compared to US$ 183.34 million in year 2016.

Memantine Market– Regional Analysis

On the basis of region, the global memantine market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

North America is expected to hold dominant position in the global memantine market, owing to increasing number of generic versions of memantine in the U.S. market. For instance, in February 2018, Lupin Limited announced the launch of its Memantine Hydrochloride Extended-Release Capsules in the U.S. market. The capsules are available in 7mg, 14mg, 21mg, and 28mg, for which company has received an approval from the U.S. FDA. These are indicated for the treatment of moderate to severe dementia of the Alzheimer’s disease.

Furthermore, Asia Pacific is expected to witness significant growth in the global memantine market, owing to increasing focus of key players in manufacturing memantine tablets. For instance, in October 2018, Dr. Reddy’s Laboratories launched memantine hydrochloride tablets in the Indian market. They are available in 5mg and 10mg, equivalent to generic version of Namenda tablets, which were already available in the U.S. market in July 2015.

Click To Reading More On Memantine Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

Visit our news Website: https://www.coherentwire.com

Plasmapheresis Device Market 2019 | Global Industry Trends, Status

Plasmapheresis is a procedure in which blood is separated into cells and plasma (liquid). The plasma is then removed and replaced with fresh frozen plasma. It is done to treat variety of autoimmune disorders such as myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, sickle cell anemia, guillain-barre syndrome, and lambert- eaton myasthenic syndrome where autoantibodies are generated harming the body.

Plasmapheresis Device Market 2018 | Global Industry Trends, Status

Plasmapheresis is a procedure in which blood is separated into cells and plasma (liquid). The plasma is then removed and replaced with fresh frozen plasma. It is done to treat variety of autoimmune disorders such as myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, sickle cell anemia, guillain-barre syndrome, and lambert- eaton myasthenic syndrome where autoantibodies are generated harming the body. Plasmapheresis can stop this growth of auto antibodies by removing the plasma that contains antibodies and replacing it with new plasma. Plasmapheresis can be performed using a semipermeable membrane-based device in combination with hemodialysis equipment.

Plasmapheresis Device Market – Drivers

For instance, on September 2018, Shire plc. (SHP) acquired sanaplasma AG, augmenting plasma collection network. The acquisition of sanaplasma AG is expected to increase Shire's access to plasma in the longer term and also widens its European plasma collection network, complementing existing core capabilities in plasma supply and manufacturing. This will also help to increase the customer base in the European region which in turn will raise demand for Plasmapheresis devices in the market.

Moreover, Biotest Pharmaceuticals Corporation (BPC), a wholly owned subsidiary of Biotest US Corporation, was acquired by Grifols Shared Services North America, Inc., in August 2018. This acquisition comprises 22 BPC plasma collection centers that manufactures critical care therapies to treat life threatening disorders. This acquisition of BPC will lead to increased availability of number of resources for plasma collections and likely to stimulate the growth of plasmapheresis devices in the global market.

Download the PDF brochure:

https://www.coherentmarketinsights.com/insight/request-pdf/2259

Plasmapheresis Device Market – Restraint

Stringent regulatory norms, and government permissions to the companies involved in plasma exchange and collections are expected to hamper growth of the market. For instance, according to an article published in Neurology India 2017, there is a need for procuring and periodically renewing permissions and licenses from regulatory authorities for providing plasma exchange.

Plasmapheresis Device Market – Regional Analysis

On the basis of region, the global plasmapheresis device market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

North America region is expected to dominate in the global plasmapheresis device market attributed to high prevalence of autoimmune diseases which require frequent plasmapheresis tests. For instance, according to American Autoimmune Related Diseases Association (AARDA) 2017 report, 50 million Americans are suffering from autoimmune disorders.

European region is expected to witness significant growth rate due to increase in the development of plasmapheresis devices. For instance, in October 2016, Fresenius Kabi, a company based in Germany, got FDA approval for its Aurora Xi Plasmapheresis System. The device is designed to improve the process of blood plasma collection, particularly speeding up the filtration process and allowing for more donors to donate in the same amount of time.

The key players operating in the plasmapheresis device market are Asahi Kasei Corporation., Terumo Corporation, Baxter International Inc., B. Braun Melsungen AG, Kawasumi Laboratories Inc., Kaneka Corporation, Haemonetics Corporation, Shanghai Dahua Medical Apparatus Co., Ltd., Infomed SA, and Fresenius SE & Co. KGaA

Click To Reading More On Plasmapheresis Device Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

Visit our news Website: https://www.coherentwire.com

Sulfadiazine Sodium Injection Market Outlook and Opportunity Analysis with Major Key Players

It is used in treating toxoplasmosis in patients with acquired immunodeficiency syndrome and in newborns with congenital infections. It is used for prevention of recurrent attacks of rheumatic fever, urinary tract infections, and chlamydial infections in humans. Sulfadiazine sodium injections are also used in veterinary animals such as cattles to manage respiratory tract infections, genitourinary infections, alimentary tract infections, and sepsis.

Sulfadiazine Sodium Injection Market– Drivers

Rising awareness for safe antibiotic uses due to widespread antibiotic resistance can drive high demand for sulfadiazine sodium injection in the global market during the forecast period. For instance, World Antibiotic Awareness Week (WAAW) observed every year in the month of November, purposes to increase global awareness of antibiotic resistance (AMR) and encourage best practices among public, health workers, and policy makers to avoid emergence and spread of antibiotic resistance.

Furthermore, the mission of Alliance for the Prudent Use of Antibiotics (APUA) started in 1981, is working to strengthen global defenses against infectious diseases by ensuring access to effective antibiotics treatment and promoting appropriate antibiotic use to reduce drug resistance. By 2018, APUA is working in 19 countries and stands as the world’s leading organization conducting research and education on antimicrobial treatment and resistance at the grassroots and global levels.

Sulfadiazine Sodium Injection Market– Restraint

Over the years, bacterial pathogens acquired resistance to sulfonamide class of antibiotics, due to mutations in pre-existing DNA, or by acquisition of antibiotic resistance genes (ARGs), which is expected to hinder growth of the sulfachloropyridazine sodium market. For instance, according to Centers for Disease Control and Prevention (CDC), in the U.S. doctors and emergency departments, prescribe at least 47 million antibiotic prescriptions each year, which are unnecessary. These are creating spread of antibiotics resistance, which might lead to severe consequences.

Download the PDF brochure:

https://www.coherentmarketinsights.com/insight/request-pdf/2313

Sulfadiazine Sodium Injection Market– Taxonomy

By Product Type

20mg/mL,40mg/mL,Others

By Patient Type

Human,Animal

Sulfadiazine Sodium Injection Market– Regional Analysis

On the basis of region, the global sulfadiazine sodium injection market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

North America is estimated to hold the leading position in sulfadiazine sodium injection market due to rising use of antibiotics. For instance, according to the U.S. Food and Drug Administration (USFDA) 2015, about 9.7 million kilograms (21.4 million pounds) of antibiotics considered important for human use were sold for use in animal agriculture.

Europe is also expected to witness significant growth in the global sulfadiazine sodium injection market, owing to rising awareness of antibiotics resistance and safe and effective practice of antibiotics use in the region. For instance, the European Antibiotic Awareness Day is celebrated on 18 November every year. On November 16, 2018, the symposium for the 11th European Antibiotic Awareness Day was hosted by the Federal Ministry for Labour, Social Affairs, Health and Consumer Protection in cooperation with the Austrian national reference centre. The agenda for the symposium focused on raising awareness about importance of prudent antibiotic use.

Click To Reading More On Sulfadiazine Sodium Injection Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

Visit our news Website: https://www.coherentwire.com

Pipettes and Accessories Market Outlook,Opportunity Analysis And Top Companies

The global pipettes and accessories market size was valued at US$ 1.3 billion in 2017 and is expected to witness a CAGR of 4.0% over the forecast period (2018 – 2026).

Pipettes are used in biotechnology, pharmaceutical, and chemical laboratories in order to transfer certain volume of liquids. Micropipettes are important in molecular biology experiments, which require microliter amounts of solutions whereas serological pipettes are used in microbiology laboratories to prepare cell cultures that require media preparations of milliliter volumes. Volume transfers with sterile cultures and solutions using instruments such as micropipettes and serological pipettes are one of several types of routine techniques performed in a laboratory. Pipette designs such as electronic pipetting, ultralight pipettes, plungers positions in more user-friendly configurations, and reducing frictional forces help in reducing strain.

Increasing research and development in the field of pharmaceuticals and biotechnology due to high prevalence of infectious diseases and cancer are the major factors driving the pipettes and accessories market growth. According to 2012 European Union Industrial R&D Investment Scoreboard, the pharmaceutical and biotechnology sectors represented 17.7% of business R&D expenditure in the world.

Pharmaceutical companies are increasingly focusing on conducting research and development activities as well as outsourcing such activities to academic and private research institutes. This in turn is increasing demand for liquid handling systems such as pipettes. Pharmaceutical companies are also increasingly outsourcing their research activities to privately-owned Contract Research Organizations (CRO) to maintain their presence in the growing pharmaceutical and biotechnology market. For instance, in May 2018, Ritter Pharmaceuticals, Inc., a manufacturer of novel therapeutic products entered into an agreement with Medpace, a CRO to conduct the first of two pivotal Phase 3 clinical trials for RP-G28 among patients with lactose intolerance.

Download the PDF brochure:

https://www.coherentmarketinsights.com/insight/request-pdf/2322

Pipettes and Accessories Market Restraints

Pipettes are extensively used for various applications and are thus exposed to various types of reagents and specimens. They can introduce quality-specific concerns regarding precision and accuracy and can also lead to safety risks, particularly while working with hazardous chemicals or specimens with a high infection risk. Furthermore, high cost of electronic pipettes can be a negative factor for the market growth. For instance, the cost of the Xplorer plus electronic single channel pipette with charging adapter is around US$ 1000. This product may not be affordable for several laboratories due to its high price. However, manual pipettes tend to be more economical, though they produce greater variability, particularly for highly sensitive or expensive pipetting applications.

Pipettes and Accessories Market - Regional Insights

On the basis of region, the global pipettes and accessories market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is the largest market for biotechnology and pharmaceutical research and manufacturing and therefore, demand for pipettes and accessories is the highest in the region. According to a study published by the International Trade Administration in 2016, the U.S. is the major hub for drug manufacturing and is expected to grow considerably in future.

Asia Pacific pipettes and accessories market is expected to witness significant growth over the forecast period. This is owing to increasing clinical trials from biopharmaceutical industry in the region due to easy patient recruitment and availability of skilled professionals to conduct research experiments. This in turn leads to increasing number of research laboratories being set up in the region, thereby propelling demand for pipettes and accessories. For instance, in March 2017, Herbalife Company associated with Syngene established a new research and development lab at Bangalore, India.

According to the India Brand Equity Foundation June 2018 report, Government of India has reduced the approval time for new facilities to propel investments for drug manufacturers under the ‘Pharma Vision 2020’. Such initiatives are expected to attract foreign investors for the development of new manufacturing units, in turn increasing demand for pipettes and accessories during the forecast period.

Click To Reading More On Pipettes and Accessories Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

Visit our news Website: https://www.coherentwire.com

Pipettes and Accessories Market Outlook,Opportunity Analysis And Top Companies

Pipettes are extensively used for various applications and are thus exposed to various types of reagents and specimens.

Clostridium Vaccine Market Global Pipeline Analysis and Trend

There is a critical need for development of prevention vaccine for this disease. Clostridium difficile, is a gram-positive bacterium, which produces an anaerobic toxin that is transmitted through fecal-oral route. Clostridium difficile infection occurs during antibiotic treatment or can be caused due to healthcare associated infection with clinical manifestation ranging from asymptomatic infection to watery diarrhea or serious intestinal condition such as colitis and colonic perforation.

Growing C. difficile infections at healthcare facilities and antibiotic resistance to treatment drugs are propelling demand for development of prophylactic options to reduce the risk of infection in vulnerable patients. A 2013 bulletin published from the Centers for Disease Control and Prevention (CDC) outlined Clostridium difficile as urgent antibiotic-resistance threats in the U.S.  

Clostridium Vaccine Market Drivers

Rising incidence and high prevalence of clostridium difficile infection is expected to boost growth of the market over the forecast period. Incidence of clostridium difficile infection has been witnessing an increase since the recent past, due to its infection recurrence and antibiotic resistance. According to Centers for Disease Control and Prevention (CDC), in 2015 around half a million people in the U.S. suffer from clostridium difficile infection in a year.

Moreover, according to National Center for Biotechnology Information (NCBI), an estimated 37,900 patients were suffering from clostridium difficile infection in Canada in 2012. A review and meta-analysis of studies published in National Center for Biotechnology Information (NCBI), 2016, conducted in China between 2010 and 2016, reported significant incidence of clostridium difficile infection in China.

Download the PDF brochure:

https://www.coherentmarketinsights.com/insight/request-pdf/2359

Currently, there is no alternative therapies apart from antibiotics available for the treatment of clostridium difficile infection and only option available is surgery (in severe cases), fecal microbiota transplant, and probiotics in case of recurrent clostridium difficile infection.

Moreover, key pharmaceutical players are engaged in conducting clinical trials for development of clostridium vaccine that can offer preventive measure in the clostridium difficile infection in near future.

For instance, in January 2017; Pfizer announced phase II study of investigational clostridium difficile vaccine candidate: PF-06425090; for the prevention of C. difficile infection. This randomized phase II study was conducted to examine the safety, tolerability, and immunogenicity of the vaccine in healthy adults 65 to 85 years of age. Pfizer initiated a phase III study in March 2017, with around 16,000 participants.  

In July 2016, Valneva SE announced the successful completion of its phase II clinical study for its prophylactic vaccine candidate VLA84 targeting on primary prevention of C. difficile infection (CDI).

Clostridium Vaccine Market Regional Analysis

North America is expected to hold a dominant position in the global clostridium vaccine market and it is expected to account for largest market share over the forecast period, owing to increased prevalence of Clostridium difficile in the U.S. and growing awareness regarding the adoption of preventive measurement in Clostridium difficile infection in this region.

For instance, according to CDC, in 2011; healthcare-associated infections (HAIs) caused by C. difficile was estimated to cause around half a million infections in the U.S. and 29,000 died within 30 days of the initial diagnosis.

Clostridium Vaccine Market Restraint

Increased risk associated with the failure of vaccine candidate during the clinical trial studies and high cost associated with late stage testing is expected to slow down commercialization of clostridium vaccine and restrain the clostridium vaccine market growth over the forecast period.

For instance, in December 2017, Sanofi terminated its phase III C. difficile clinical trial studies, due to the results of an interim trial analysis, which stated low probability of success with its C. difficile candidate. Moreover, discontinuation of Sanofi’s C. difficile vaccine program is expected to offer great future opportunity for Pfizer and Valneva to offer its vaccine to patients after getting the satisfactory regulatory approval in the future.

Click To Reading More On Clostridium Vaccine Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

Visit our news Website: https://www.coherentwire.com

Biobanking Equipment Market Insights ,Trends And Growth

The global biobanking equipment market was valued at US$ 1,778.3 million in 2017, and is expected to witness a robust CAGR of 7.5% over the forecast period (2018 – 2026).

The biobanks typically handle human biospecimens such as blood, tissue, and urine. They are established within academic medical or research institutions, pharmaceuticals or biotechnological companies or as a standalone organizations. Biobanks can be disease-oriented or population-based and they can contain a variety of samples such as blood, enzymes, organ tissue, urine, DNA, RNA, and cell lines.

The biobanks also help in precision medicine to discover several new treatments that are tailored for specific characteristic such as person’s genetic makeup or genetic profile of an individual tumor, which helps to transform the treatment. Precision medicine is effective in Alzheimer’s disease, arthritis, cardiovascular diseases, diabetes, oncology, psychiatric disorder, neurodegenerative disease, obesity, and pain. Furthermore, the biobanks are used to store the biological samples such as blood, cell lines, tissues, and DNA from patients with rare disease. For instance, Orphanet, the European portal for rare disease and orphan drugs developed a comprehensive disease coding systems and a database listing more than 100 rare disease biobanks in Europe.

Increase in research and development in molecular biology and precision medicine is also expected to favor growth of the biobanking equipment market. In 2014, the Biobanking and BioMolecular resources Research Infrastructure–European Research Infrastructure Consortium (BBMRIERIC), an organization for biobanking in Europe, was established to provide a focal point for biobanking activities in Europe. It also provides access to quality-controlled human biological samples and associated data for cross-biobanking research. The biobanks also play a critical role in cancer research, as they provide access to the status of human genome. The complex networks of interactions between biomolecules and the clinical and functional consequences of their alteration can be studied on human genome instead of human biological specimens, which is easy for discovering new mechanisms involved in cancer. Biobanks are rapidly expanding in biomedical science domains including molecular pathology, molecular and genetic epidemiology, and pharmacogenomics.

Download the PDF brochure:

https://www.coherentmarketinsights.com/insight/request-pdf/2365

Biobanking Equipment Market Restraints

One of the major challenges in biobanking is to ensure an effective and ethical access to biological samples and associated clinical data. Trust between donors and researchers must be built so that individuals would like to donate to biobanks. Moreover, the stringent regulatory policy affects the biobanking equipment market, as the ‘The Privacy Rule’ (2002) established by U.S. Department of Health & Human Services have set new standards and regulations to protect the patients from inappropriate disclosures of their protected health information that may affect a patient's access to insurance, employability, and privacy.

Biobanking Equipment Market - Regional Insights

On the basis of region, the global biobanking equipment market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. In 2018, North America accounts for the largest revenue share in the global biobanking equipment market, followed by Europe. This is mainly attributed to increased awareness and initiatives related to precision medicine in the region. In 2015, the U.S. government announced the launch of Precision Medicine Initiative, which aimed to revolutionize the treatment to improve the health.

Asia Pacific biobanking equipment market is expected to witness significant growth during the forecast period due to increasing biobanking related activities in the region. Asian countries, especially China, Japan, and Korea are very active in biobanking activities under the strategic plans coordinated by their governments. They also proactively established networks for biobanks of Asia to facilitate resource and expertise sharing. For instance, in 2014, for collection of human specimens, Japan’s Ministry of Education, Culture, Sports, Science and Technology (MEXT) and Ministry of Health, Labor, and Welfare (MHLW) collaborated in managing human biobank networks of BioBank Japan (BBJ), National Center Biobank Network (NCBN), and Tohoku Medical Megabank Organization (ToMMo) biobank project.

Click To Reading More On Biobanking Equipment Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

Acetazolamide Market-Global Industry Insights And Trends

The global acetazolamide market size was valued at US$ 183.2 Mn in 2017, and is expected to witness a CAGR of 4.8% during the forecast period (2018 – 2026).

Acetazolamide is carbonic anhydrase inhibitor, used in adjuvant treatment of chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma, epilepsy, edema due to congestive heart failure, drug-induced edema, and acute mountain sickness in climbers. Acetazolamide promotes acclimatization to altitude, increases bicarbonate secretion by the kidneys, induces metabolic acidosis, and stimulates ventilation. Furthermore, according to the BMJ Journal, September 2012, acetazolamide in doses of 250 mg, 500 mg, and 750 mg daily are more effective compared to placebo for preventing acute mountain sickness. In addition, acetazolamide 250 mg daily is the lowest effective dose to prevent acute mountain sickness.

Acetazolamide is used to prevent high altitude illness in most people, which is characterized by headache, nausea, vomiting, and tiredness (often called acute mountain sickness), but may affect the brain or the lungs in different individuals. As per the study published in Cochrane Journal, in June 2017, acetazolamide is an effective and better treatment for the prevention of acute high altitude illness (HAI) in dosages of 250 to 750 mg/day, when compared to a placebo. Acetazolamide prevents acute mountain sickness and has fewer side effects than alternative drugs such as dexamethasone. According to BMJ journal, May 2018, prescribing acetazolamide for travel is an optional service and not included in the general practitioner’s contract in the U.K.

Download the PDF brochure: https://www.coherentmarketinsights.com/insight/request-pdf/2396

Researchers at the University of Chicago investigated acetazolamide, and published in the journal Science Translational Medicine, July 2018, stating that, altitude sickness drug, acetazolamide, helps to overcome resistance to chemotherapy drug temozolomide (TMZ). TMZ is frequently used in the treatment of gliomas, but some patients do not respond to the treatment. With the addition of acetazolamide, researchers identified an improvement in survival rates, in pre-clinical models of glioma. According to this study, acetazolamide when taken with TMZ, resulted in 30 to 40 percent increase in survival in animal models. Application of acetazolamide could be used as an alternative treatment solution for reducing resistance to chemotherapy in the treatment of gliomas, which offer lucrative growth opportunities for the drug in the market in the near future.

Furthermore, along with chronic simple (open-angle) glaucoma, secondary glaucoma and acute mountain sickness in climbers; acetazolamide is also indicated for adjective treatment of edema due to congestive heart failure; drug-induced edema; centrencephalic epilepsies.

Increasing prevalence of glaucoma and associated risk factors such as high myopia, diabetes, eye surgery or injury, high blood pressure, increased usage of corticosteroids, and family history of glaucoma among the global population are expected to offer conducive future growth for acetazolamide drug manufacturers. As a sustained release capsule of Acetazolamide taken a day, offers a substantial pressure-lowering effect that lasts at least 23 hours. Treatment with acetazolamide helps to reduce eye pressure, which aids in preventing eye damage. Acetazolamide works by blocking the action of an enzyme called carbonic anhydrase thereby, reducing the amount of fluid secreted in the front part of eye, thus lowering eye pressure. For instance, according to the study published in the Journal of Ophthalmology (2014), an estimated 64.3 million people (aged 40-80 years) in 2013, were affected with glaucoma, which would increase to 76.0 million in 2020, and 111.8 million in 2040.

According to the International Agency for the Prevention of Blindness, 2017, glaucoma is the second leading cause of blindness and leading cause of irreversible blindness worldwide. With primary angle closure glaucoma (PACG) being the most common in South-East Asia  while primary open-angle glaucoma (POAG) is mostly found among white Caucasians and individuals of Africa.

Among region, Asia Pacific is expected to be conducive region for the acetazolamide market growth. This is mainly owing to growing healthcare infrastructures, high prevalence of glaucoma, and associated risk factors such as diabetes and high blood pressure cases among the population of the region. For instance, according to American Academy of Ophthalmology (AAO), November 2013, glaucoma is the most common cause of preventable, irreversible blindness worldwide, among which primary open-angle glaucoma (POAG) is responsible for 12.3% of blindness. Furthermore, according to same source, POAG’s prevalence is estimated to be the highest among the people of China, intermediate in Japan, and lower in Europe and India. Therefore, these driving factors are expected to propel growth of acetazolamide market in Asia Pacific.

Click To Reading More On Acetazolamide Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

Visit our news Website: https://www.coherentwire.com

Protein Expression Systems Market Share, Outlook, and Opportunity Analysis

The global protein expression systems market size was valued at US$ 1.2 billion in 2017, and is expected to witness a CAGR of 11.1% over the forecast period (2018 – 2026).

Protein expression has become an important laboratory technology in biochemistry, molecular biology, and protein research as well as other scientific research fields, which require functional proteins for their research. The technology can also provide substrates or enzymes required for further analysis. Many chemically competent bacterial cells such as E. coli cells, suitable for protein expression and transformation, are available as research kits. Other commonly used protein expression systems include cell systems derived from insect, plants, yeast, and mammalian cells.

Rising incidence of various diseases such as cancer, cardiovascular conditions, and genetic disorders is the major factor driving growth of protein expression system market. For instance, protein-based drugs such as insulin, can treat a wide variety of conditions with remarkable effectiveness. Moreover, high efficiency of protein therapeutics and minimum risk of side effects associated with protein therapeutics is attracting manufacturers to invest in the protein expression systems research and development.

Furthermore, advances in protein-engineering technologies allow drug developers and manufacturers to modify and develop desirable functional characteristics of proteins of interest while maintaining product efficacy and safety. For instance, in 2017, HumanZyme Inc., a leading supplier of novel recombinant human proteins and growth factors expressed in human cells, announced the launch of HumanKine(r) Interferon gamma (IFN gamma) expressed from HEK293 cells. IFN gamma protects against bacterial, viral, and protozoan infections.

Get HOLISTIC Request Sample Copy Of This Business Report:

https://www.coherentmarketinsights.com/insight/request-sample/2383

Protein Expression Systems Market Restraints

Despite tremendous application of protein therapeutics in R&D and drug development, in some cases, the production of recombinant proteins can be expensive, complex, and time-consuming. Moreover, the recombinant proteins produced in cells may not be the same as the natural forms, therefore the difference can reduce effectiveness of therapeutic recombinant proteins and even cause side effects.

Protein Expression Systems Market - Regional Insights

On the basis of region, the global protein expression systems market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America protein expression systems market is expected to generate significant revenue share during the forecast period, owing to increasing biopharmaceutical research and development investment and activities from public and private organizations. For instance, according to Pharmaceutical Research and Manufacturers of America (PhRMA), 2016, member companies invested around US$ 58.8 billion in research and development in 2015, of which, majority was by all biopharmaceutical companies in the U.S.

Asia Pacific protein expression systems market is anticipated to grow at highest CAGR during the forecast period. The lucrative growth in the region is majorly attributed to rising interests of regional manufacturers in protein therapeutics. For instance, in 2016, Takeda Pharmaceutical and Crescendo Biologics collaborated and license agreement for the discovery, development and commercialization of Humabody-based therapeutics for cancers with a high unmet medical need. Humabodies are a novel class of extremely small, robust, and potent protein therapeutics.

The demand for protein therapeutics has increased considerably, owing to increase in prevalence of chronic diseases and development of plasma-derived therapies. In recent years, proteins expression systems have gained significant traction for therapeutic applications and the number of proteins launched or approved into clinical trials has continually increased. According to the National Center for Biotechnology Information (NCBI) data of 2017, the U.S. Food and Drug Administration (FDA) approved more than 140 recombinant therapeutic proteins for human use and several hundred are currently in development.

However, high cost associated with therapeutic proteins and stringent government regulations towards approval of protein therapies are expected to hinder market growth. For instance, in India, a vial of Avastin (Bevacizumab mostly produced by the mammalian cell expression system), a monoclonal antibody, cost between US$ 372.65 to US$ 402.46. Moreover, immunogenicity is also a major concern for all recombinant drugs, as all biotechnologically produced therapeutics may exhibit some form of immunogenicity.

Click To Reading More On Protein Expression Systems Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

Visit our news Website: https://www.coherentwire.com

Newborn Screening Market is expected to witness a CAGR of 12.4% 

The global newborn screening market size was valued at US$ 561.5 million in 2018, and is expected to witness a CAGR of 12.4% over the forecast period (2018 – 2026).

Newborn screening describes various tests that are performed during first few hours or days of an infant’s life. These tests have the potential for preventing severe health problems, including death. Newborn screening has evolved from a simple urine or blood screening test to a more comprehensive and complex screening system capable of detecting over 50 different conditions. Newborn screening tests measure a number of markers in infant’s blood that can be either decreased or increased if an infant has certain diseases. Currently, conditions such as cystic fibrosis (CF), congenital hypothyroidism, phenylketonuria (PKU), and around 22 other metabolic conditions that affect protein or fat metabolism can be diagnosed through newborn screening tests.

Several governments are taking initiative in increasing awareness about newborn screening tests and are offering free screening services in some regions. For instance, in September 2018, the Florida Department of Health launched the Newborn Screening (NBS) Web Order Application. This statewide initiative has been developed to ensure efficiency and accuracy of newborn screening information submitted to the Bureau of Public Health Laboratories.

Download the PDF brochure: https://www.coherentmarketinsights.com/insight/request-pdf/2192

Moreover, novel biomarkers and analytical technologies are driving the evolution of Newborn Screening (NBS) programs. For instance, a rapid and highly sensitive point-of-care testing device has been developed and commercialized for the diagnosis of Sickle Cell Disease (SCD). According to a BMC Medicine Journal study 2015, SCD test demonstrated 99% specificity and 99% sensitivity for the diagnosis of several hemoglobin (Hb) variants: sickle cell trait (Hb AS), sickle cell anemia (Hb SS), Hb AA, Hb AC, and Hb SC, and requires only 5 μL of blood. Similarly, Next-Generation Sequencing (NGS) technologies are expected to impact newborn screening in the near future.

On the basis of region, the global newborn screening market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. By 2026, North America and Europe are expected to generate major revenue share in the global newborn screening market, owing to the presence of a better reimbursement structure, development of well-equipped healthcare infrastructure, and availability of trained medical professionals. According to the U.S. government, for the 2018 fiscal year, the Newborn Screening Quality Assurance Program at the CDC is funded at US$ 8.4 million and the Heritable Disorders program at Health Resources and Services Administration (HRSA) is funded at $13.88 million. The most common newborn screening tests in the U.S. include, hypothyrodism, galactosemia, PKU (phenylketonuria), and sickle cell disease. Increasing government funding in Europe for NBS within a national health service or a statutory health insurance, is expected to drive newborn screening market growth in Europe.

Asia Pacific newborn screening market is expected to foresee highest growth rate during the forecast period, owing to increasing incidences of premature births, high birth rates in countries such as China and India, and increasing healthcare awareness among regional population. According to WHO, 2012 report, most neonatal deaths occur in Asia, which accounted for 40% of the global neonatal deaths. Moreover, in India, less than 1% of infants are screened and over 1.6 million infants are born with birth defects, annually. These factors are expected to propel growth of the global newborn screening market in the region.

Click To Reading More On Newborn Screening Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

Visit our news Website: https://www.coherentwire.com

Glycated Albumin Market By Geography, Trends And Growth

Glycated albumin is glucose bonded to an albumin molecule. Protein molecule i.e. albumin is present in the blood, major body organs, and body fluids. Function of albumin is to maintain shape of the cell and distribute hormones and nutrients.

The amount of albumin decreases in the body when blood glucose levels are low, whereas increases when blood glucose levels are high. Glycated albumin is measured during initiation of diabetes therapies to determine medication dose for treatment of diabetes.

According to a study conducted by American Association for Clinical Study, in 2011, glycated albumin is described as a novel biomarker for the detection and management of diabetes. Treatment of diabetes requires glycemic control. There are various measurements used to provide indicators, which include glycated hemoglobin (HbA1c), 1, 5-anhydroglucitol (1,5AG), and glycated albumin.

Glycated hemoglobin (HbA1c) indicates the glycemic level during the first three months of diabetes incidence. This measurement is useful for the confirmation of short-term therapeutic efficacy during initiation of the treatment for diabetes.

Increasing number of approvals of novel glycated albumin products in the market is expected to fuel the glycated albumin market growth in the near future

In 2015, Asahi Kasei Pharma Corporation received CE Marking for its new Lucica Glycated Albumin-L, an in vitro diagnostic assay kit, for glycated albumin (GA-L) in Europe. Lucica Glycated Albumin-L is used for the quantitative measurement of glycated albumin in human serum on compatible clinical chemistry analyzers. In 2015, Lucica Glycated Albumin-L received approval in Taiwan, in 2013 it received approval in Indonesia, and Korea.

In 2011, Diazyme Laboratories, Enzymatic glycated serum protein (GSP, Glycated Albumin) Assay Kit received approved by the U.S. Food and Drug Administration (FDA). Enzymatic glycated serum protein (GSP, Glycated Albumin) assay is two part liquid stable reagent, which can be used with various types of automated clinical chemistry analyzers. This product provides additional diagnostic values to clinical practices in diabetes management and screening. Thus, increasing approval of novel glycated albumin kits launched by key players in the market is expected to create a lucrative environment for the global glycated albumin market growth.

The global glycated albumin market value was US$ XX Mn in 2017, and is expected to witness a CAGR of XX% over the forecast period (2018 – 2026).

Download the PDF brochure:

https://www.coherentmarketinsights.com/insight/request-pdf/1957

Increasing prevalence of diabetes is expected to fuel the glycated albumin market growth

According to the International Diabetes Federation (IDF), the global diabetic population in 2015 was around 415 million and is expected to reach 642 million by 2040. Thus, rising prevalence of diabetes is expected to increase the demand for glycated albumin for its diagnosis, which in turn is expected to fuel the global glycated albumin assay market growth over the forecast period.

North America is expected to hold a dominant position in the global glycated albumin kits market due to high prevalence of diabetes in region. For instance, according to data published by American Diabetes Association in 2015, around 1.25 million children and adults in the U.S. were suffering from type 1 diabetes and around 84.1 million people aged 18 years and above had prediabetes.

Asia Pacific glycated albumin market is expected to show significant growth owing to increasing number of approvals for novel glycated albumin kits in the region. For instance, in 2015, Lucica Glycated Albumin-L by Asahi Kasei Pharma Corporation received approval in Taiwan. Company also received approval for its Lucica Glycated Albumin-L in Indonesia and Korea.

This report provides in-depth analysis of glycated albumin market and provides market size (US$ Million) and cumulative annual growth rate (CAGR %) for the forecast period (2018 – 2026), considering 2017 as the base year

It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players

It profiles leading players in the global glycated albumin market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies, and future plans

Key companies covered as a part of this study include Lifespan Biosciences, Biomatik Corporation, Abbexa Ltd., G Biosciences, DRG International, Inc., Amsbio LLC, Signalway Antibody LLC, United States Biological, Diazyme Laboratories, Abnova Corporation, Maccura Biotechnology Co. Ltd., Exocell Inc., Biorbyt Ltd., and Epinex Diagnostics Inc.

Click To Reading More On Glycated Albumin Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

Visit our news Website: https://www.coherentwire.com

Glycated Albumin Market By Geography, Trends And Growth

Glycation is the process of bonding of a sugar molecule. For instance, glucose to a protein or a lipid molecule such as albumin